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Abstract
Background: DNA vaccines are a promising approach to vaccination since they circumvent the problem of vector-induced
immunity.DNAplasmidcytokineadjuvantshavebeenshowntoaugmentimmuneresponsesinsmallanimalsandinmacaques.
Methodology/Principal Findings: We performed two first in human HIV vaccine trials in the US, Brazil and Thailand of an RNA-
optimized truncated HIV-1 gag gene (p37) DNA derived from strain HXB2 administered either alone or in combination with dose-
escalation of IL-12 or IL-15 plasmid cytokine adjuvants. Vaccinations with both the HIV immunogen and cytokine adjuvant were
generally well-tolerated and no significant vaccine-related adver s ee v e n t sw e r ei d e n t i f i e d .As m a ll number of subjects developed
asymptomatic low titer antibodies to IL-12 or IL-15. Cellular immunogenicity following 3 and 4 vaccinations was poor, with
response rates to gag of 4.9%/8.7% among vaccinees receiving gag DNA alone, 0%/11.5% among those receiving gag DNA+IL-15,
and no responders among those receiving DNA+high dose (1500 ug) IL-12 DNA. However, after three doses, 44.4% (4/9) of
vaccinees receiving gag DNA and intermediate dose (500 ug) of IL-12 DNA demonstrated a detectable cellular immune response.
Conclusions/Significance: This combination of HIV gag DNA with plasmid cytokine adjuvants was well tolerated. There were
minimal responses to HIV gag DNA alone, and no apparent augmentation with either IL-12 or IL-15 plasmid cytokine adjuvants.
Despite the promise of DNA vaccines, newer formulations or methods of delivery will be required to increase their
immunogenicity.
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Introduction
DNA vaccines theoretically have potential to generate immune
responses to common pathogens. The majority of HIV vaccines
evaluated to date have relied on viral vectors such as vaccinia or
adenovirus to deliver antigen [1–5]. DNA expresses the antigen of
interest without the need for a vector delivery system; therefore
this non-live vaccine approach circumvents the problem of vector-
induced immune responses. In addition to the safety of this
approach, DNA vaccines have the ability to induce cellular
immune responses, which is in contrast to killed or subunit-based
vaccines [6].
Several delivery methods for DNA vaccines have been tested in
animals and in humans. The basic concept is the uptake of DNA
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29231into cells (skin, subcutaneous cells, muscle, and antigen presenting
cells), where it reaches the nucleus via the host cellular machinery.
Once there, gene transcription and protein production takes place.
The cell provides the post-translational modifications to these
proteins, that are then processed and presented in the context of
HLA class I and class II molecules [1].
The major drawback of DNA vaccines has been a reduced level
of immunogenicity in humans compared to animal models [7–10].
The first pre-clinical studies demonstrated that ‘‘naked’’ DNA
could protect from virulent influenza [11]. While macaque and
human studies have shown that DNA vaccines are not as
immunogenic as vaccine vectors such as adenovirus [8,12],
combination prime-boost protocols with an HIV DNA priming
regimen followed by adenovirus type 5-HIV DNA can increase
the magnitude and qualitatively alter immune responses in
macaques [13,14] and humans [14–16]. A similar effect has been
shown in a recent human trial of DNA priming followed by MVA
boost [17]. However, some combination vaccines may be difficult
to administer, thus methods to augment immunogenicity of DNA
vaccines are desirable.
One approach to augment the immunogenicity of DNA is to
combine the DNA plasmid of the gene of interest along with a
plasmid cytokine adjuvant [18]. Two promising cytokine adjuvants
include interleukin-12 [19] and interleukin-15 [20]. IL-12 has
been shown to be a key cytokine for the induction of cellular
immune responses. IL-12 is a p70 disulfide-linked heterodimer
composed of two separately encoded subunits, a heavy chain of
40 kDa and a 35-kDa light chain that was originally cloned from B
lymphoblastoid cell lines [21,22]. Although p35 gene transcripts
are rather ubiquitous, p40 transcripts are found exclusively in cells
producing biologically active IL-12, which include monocytes,
macrophages, dendritic cells (DCs), polymorphonuclear leukocytes
(PMN), and B cells [23]. The importance of this cytokine is
highlighted by the observation that genetic defects in IL-12
predispose to infections with intracellular pathogens such as
salmonella and tuberculosis [24–26]. IL-15 is a glycoprotein of 14–
15 kDA in size and is produced by monocytes, DCs and epithelial
cells. It is a member of the common cytokine receptor c-chain
family, and was initially characterized as a T cell growth factor
with similar in vitro properties as IL-2 [27–29]. IL-15 is important
in the initial stimulation of the proliferation of activated T and B
cells on antigenic stimulation, as well as the maintenance and
activation of natural killer (NK) cells. Furthermore IL-15 inhibits
IL-2 induced cell death and is an important cytokine for the
development of long-lived memory T cell responses [30–32]. Here
we summarize the first human trials combining vaccination with a
plasmid expressing HIV-1 gag p37 and either an IL-12- or IL-15
expressing plasmid.
Methods
Study design
The protocols for these trials and supporting CONSORT
checklist are available as supporting information; see Checklist S1
and Protocols S1 and S2. HVTN 060 and 063 were both
multicenter, randomized, placebo-controlled, double-blind Phase
1 trials conducted in the US, Brazil (063), and Thailand (060)
(Figures 1 and 2).
Participants
Study subjects were healthy HIV-1 uninfected adults (18 to 49
years old), who met eligibility criteria based on medical history,
physical exam, and laboratory tests, including a CBC, serum
creatinine, ALT, AST, CPK, alkaline phosphatase, and urinalysis.
Volunteers were excluded for an allergy to amide-type local
anesthetics. Participants provided signed informed consent in their
native language. Reactogenicity and adverse events were graded
based on the HVTN Table for Grading Severity of Adverse Experiences.
Ethics
The studies were approved by the US Food and Drug
Administration, the Recombinant DNA Advisory Committee
(RAC), the National Health Surveillance Agency Brazil (AN-
VISA), the National Commission on Ethics in Research (CONEP)
Brazil, the Thai Food and Drug Administration, the Committee
for Research on Humans, Ministry of Public Health (Thailand),
and study site institutional review boards and biosafety committees
(Vanderbilt University Medical Center, Nashville; TN, University
of Alabama Medical Center, Birmingham, AL; University of
Rochester Medical Center, Rochester, NY; Fred Hutchinson
Cancer Research Center, Seattle, WA, University of Maryland at
Baltimore, Baltimore, MD; Columbia University School of
Medicine, New York, NY; Chiang Mai Ram Hospital, Chiang
Mai, Thailand; Centro de Referencia e Treinamento em DST/
AIDS, Sao Paulo Brazil; University of Pennsylvania, Philadelphia,
PA; and Brigham and Women’s Hospital, Boston, Massachusetts).
Interventions
Study participants were randomized to receive gag DNA alone
(1500 ug), gag DNA + dose escalations of IL-12 plasmid (100, 500,
or 1500 ug) (HVTN 060), or gag DNA + dose escalations of IL-15
plasmid (100, 500, or 1500 ug) (HVTN 063). In study 060, 30
individuals received an additional 2 vaccinations with gag DNA
alone, and 30 individuals received 2 vaccinations with gag
DNA+1500 ug of IL-12 plasmid. In study 063, 30 individuals
received an additional 2 vaccinations with gag DNA+1500 ug of
IL-15 plasmid, and 30 individuals received an additional 2
vaccinations with gag DNA+1500 ug of IL-12 plasmid. Vaccina-
tions were given intramuscularly at months 0, 1, and 3, and
months 6 and 9 where applicable (Figure 2).
Study agents
The HIV-1 gag DNA vaccine is derived from strain HXB2. It
was RNA optimized by introducing multiple silent point mutations
within the coding region that disrupt endogenous inhibitory
sequences that impede nuclear export thus allowing for high level
Rev-independent expression [33–35]The plasmid backbone in-
cludes a eukaryotic gene expression unit that contains elements
from the human cytomegalovirus (hCMV) immediate early
promoter/enhancer and the bovine growth hormone (BGH)
polyadenylation signal, a chimeric kanamycin resistance gene, and
a pUC bacterial origin of replication. In vitro expression analyses
this HIV gag p37 DNA was performed in both African green
monkey kidney (COS) and human rhabdomyosarcoma (RD) cells.
Cells were transfected with 1 mg of the HIV gag-expressing DNA in
the presence of a transfectant agent, Fugene (Roche); culture
supernatants and cell lysates were examined for biological activity
48 hours later by assaying (ELISA) for HIV Gag. There was a
significant enhancement in Gag expression (up to 200-fold) of the
RNA-optimized gag p37 over that observed with the original full-
length HIV-1 gag DNA in a qualified assay [[[John, can you look at
this section and modify? Is there a reference for the ‘‘qualified
assay’’ part, or is this sufficient? SK]. The vaccine is formulated in
30 mM citrate buffer pH 6.5 containing 150 mM NaCl, 0.01%
ethylenediamine tetraacetic acid (EDTA), and 0.25% bupivacaine-
HCl.
The IL-12 DNA adjuvant is a dual promoter expression plasmid
which expresses the genes encoding human IL-12 proteins p35
DNA Vaccination with HIV-1 Gag & Cytokine Plasmids
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doi:10.1371/journal.pone.0029231.g001
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under the control of the hCMV promoter/enhancer and the SV40
(simian virus 40) polyadenylation signal. The p40 subunit is under
the control of the SCMV (simian cytomegalovirus) promoter and
the BGH (bovine growth hormone) polyadenylation signal. The
plasmid contains a chimeric kanamycin resistance gene and a
pUC bacterial origin of replication. The plasmid adjuvant is
formulated in 30 mM citrate buffer pH 6.5 containing 150 mM
NaCl, 0.01% ethylenediamine tetraacetic acid (EDTA), and
0.25% bupivacaine-HCl.
The IL-15 DNA adjuvant encodes the human IL-15 gene within
a DNA plasmid expression vector. The IL-15 gene is under the
control of the hCMV promoter and the BGH polyadenylation
signal. The plasmid also contains a chimeric kanamycin resistance
gene and a ColE1 bacterial origin of replication. The IL-15 gene
has been optimized for high-level expression, with removal of the
IL-15 signal peptide sequence in exchange for that of rhesus IL-15,
and inclusion of Kozak sequences for efficient translation. The IL-
15 DNA is formulated in 30 mM citrate buffer pH 6.5 containing
150 mM NaCl, 0.01% EDTA and 0.25% bupivacaine-HCl.
Vaccine and plasmid cytokine aduvants were supplied by
Wyeth, now Wyeth LLC and a wholly owned subsidiary of Pfizer
Inc.
For both trials, the placebo was sodium chloride injection USP,
0.9%.
Laboratory Assays
Evaluation for cytokine neutralizing antibodies. The
presence of cytokine neutralizing antibody was detected by a
reduction in the activity of a cytokine responsive cell line. HVTN
063 participants were tested for IL-15 antibodies either at baseline
and 2 weeks following the 3
rd vaccination (3 dose groups) or 2
weeks following the 5
th vaccination (5 dose groups). For the IL-15
neutralization assay the CTLL-2 cell line is used, which
proliferates in response to IL-15. To begin the assay, serum is
mixed with an amount of IL-15 known to produce approximately
90% maximum proliferation. After 1 hour incubation of IL-15
and serum antibody, CTLL-2 cells are added to the mixture and
cultured for 3 days after which time the proliferation of cells is
measured. To measure proliferation, sodium 3,39-[1(phenylamino)
carbonyl]-3,4-tetrazolium]-3is(4-methoxy-6-nitro) benzene sulfonic
acid hydrate is metabolized by live cells to form a colored
product, which can be measured in ELISA plate readers. Thus,
the presence of anti-IL-15 antibody would result in less colored
product being formed. Each sample is serially diluted starting
from neat serum and its concentration is calculated relative to a
reference standard. The results of the assays are expressed in
Neutralization units (NU) per ml. One NU is defined as the
amount of antibody that neutralizes 1 International Unit (IU) of
cytokine. The lower limit of quantitation is 11 NU/ml and a
negative test is given a value of 6 NU
HVTN 060 participants were tested for IL-12 neutralization
activity in serum at baseline and 2 weeks following the 1
st,2
nd and
3
rd vaccinations and 3.5 months after 3
rd vaccination (3 dose
groups). In addition, those randomized to gag DNA + IL-15 (3
doses) + either IL-15 or IL-12 (2 doses) were tested 2 weeks
following the 5
th vaccination. The IL-12 neutralization assay uses
a natural killer cell line, NK92-MI, as the IL-12 responsive cell
line. In this assay, the response of the NK92-MI cells to the
presence of IL-12 is the secretion of IFN-c, not cellular
proliferation. The IFN-c secreted in the culture supernatant is
quantified in a sandwich ELISA using commercial reagents. The
lower limit of quantitation for this assay was determined to be
8 NU/ml, and a negative test is given a value of 4 NU/ml. During
clinical testing with this assay, high backgrounds in pre-
vaccination serum were encountered such that results to
approximately 30 NU/ml could be considered negative.
Immunogenicity evaluations
Cellular assays. Ex vivo T cell responses were assessed using
a validated IFN-c ELISpot assay with a panel of two consensus
Clade B gag peptide pools. The assays were performed using
cryopreserved peripheral blood mononuclear cells. Specimens
were excluded from analysis if: the participant was HIV-1 infected;
the visit took place outside of the allowable visit window; cell
viability was less than 66% upon thawing; the result was deemed
unreliable by the lab, the mean of the medium-only wells was
greater than 6 spot forming cells (SFC)/200,000 PBMC; the mean
Figure 2. Study schema for HVTN 060/063. N3-5 – Number of participants randomized to either 3 dose or 5 dose regimen; N5 – Number of
participants randomized to a 5 dose regimen.
doi:10.1371/journal.pone.0029231.g002
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200,000 PBMC; the mean for the negative control wells was
greater than 20 SFC/200,000 PBMC; or results were available for
fewer than 4 of the 6 negative control wells. Also, data for a
specific peptide pool were excluded if: 1) there were results from
fewer than 2 of the 3 experimental wells or 2) the ratio of the
variance of the experimental wells to the median of the
experimental wells +1 was greater than or equal to 25 SFC/
200,000 PBMC.
Humoral assays. Serological tests for binding antibodies to
p55 were assessed with a validated ELISA using single serum
dilutions (1/100). Any of the time points that yielded positive
results in the initial ELISA were subject to midpoint titration
ELISA employing 6 serial dilutions of serum beginning at 1/100.
Objectives
The primary objective of the study was to assess the safety,
reactogenicity, and tolerability of gag DNA alone (1500 ug), gag
DNA + dose escalations of IL-12 plasmid (100, 500, or 1500 ug)
(HVTN 060), or gag DNA + dose escalations of IL-15 plasmid
(100, 500, or 1500 ug) (HVTN 063) in healthy adults 18 to 49
years. Secondary objectives included the assessment of the
immunogenicity of gag DNA alone or in combination with plasmid
cytokine adjuvants.
Outcomes
Initial safety assessment included visual inspection of the
injection 30 minutes post injection, and subsequent safety
assessments were performed at up to 11 visits depending on
receipt of 3 vs 5 vaccinations (on days 14, 28, 42, 84, 98, 168, 182,
273, 287, 364, and 455). Reactogenicity and adverse events were
graded based on the HVTN Table for Grading Severity of Adverse
Experiences. Ex vivo T cell responses were assessed with a validated
IFN-c ELISpot assay using cryopreserved peripheral blood
mononuclear cells (PBMC) from HVTN 060 samples obtained
at baseline, 2 weeks post 3
rd vaccination, and 2 weeks post 4
th and
5
th vaccinations (5 dose groups only), and from 063 samples at
baseline and 2 weeks post 3
rd vaccination (3 dose groups only), and
2 weeks post 4
th vaccination (5 dose groups only). Humoral assays
from HVTN 060 and HVTN 063 samples were performed at
baseline. Subsequent samples from HVTN 060 were performed 2
weeks post 3
rd vaccination (3 dose groups) and 2 weeks post 5
th
vaccination (5 dose groups) and from 063 samples at 2 weeks post
3
rd vaccination (3 dose groups) and 2 weeks post 4
th vaccination (5
dose groups).
Sample size and randomization
Groups in the IL-12 (060) and IL-15 (063) dose escalation
phases, which received 3 vaccinations, were each randomized with
a ratio of 10 vaccine to 2 placebo. Groups receiving products at
the maximum dose with 5 vaccinations were randomized with a
ratio of 30 vaccine to 6 placebo. Placebos were included primarily
to maintain blinding, provide some safety reference data, and to
provide controls for immunogenicity assays. Sample size was
selected based on the ability to detect rare safety events since these
were first in human trials. Within vaccine groups of size 30 (10),
there was a 90% chance of observing at least 1 adverse event if the
true rate of an event was at least 8% (21%).
Randomization was conducted independently for the two trials
and stratified by country. Randomization assignments were
computer generated by a centralized statistical and data
management center and provided to site pharmacists. Participants,
site staff other than the site pharmacists, laboratory personnel
responsible for endpoint assays, and investigators were blinded as
to treatment assignments during the conduct of the trial.
Statistical methods
All participants received at least one vaccination and are
therefore included in the safety analyses. For vaccine reactions, the
maximum severity of pain and/or tenderness and of systemic
symptoms was calculated for study injections 1–3 and 4–5
separately. Systemic symptoms included malaise and/or fatigue,
myalgia, headache, nausea, vomiting, chills and arthralgia. No
statistically significant differences were observed for vaccine
reaction symptoms between groups receiving 100 or 500 ug doses
of either IL-12 or IL-15 adjuvant, so the two dose groups were
combined for each adjuvant in Figure 3. Differences in the
distribution of severity of vaccine reactions were assessed with
exact Wilcoxon rank sum tests.
For the IFN-c ELISpot assay, to determine a positive response
to a specific peptide pool, the distribution free method of Moodie,
et al [36] was used. This approach uses a bootstrap test to test the
null hypothesis that the mean of the experimental wells was equal
to twice the mean of the negative control wells, versus the
alternative hypothesis that the experimental mean was greater
than twice that of the negative control mean based on log10
transformed data. The method adjusted for the two peptide pools
by calculating step-down maxT adjusted p-values. Peptide pools
with adjusted one-sided p-values#0.05 were declared positive. In
addition to a significant p-value, the mean background-subtracted
response for the peptide pool had to be .50 SFC/10
6 PBMC for
the peptide pool to be considered positive. The purpose of this
criterion was to require a minimal demonstration of biological
activity. If either of the peptide pools was positive, then the overall
response was considered positive.
For the ELISA assay, response to an antigen was considered
positive if the differences in optical densities between duplicate
antigen-containing and non-antigen containing wells was .0.2.
For the IL-12 and IL-15 neutralization assays, values greater than
30 and 11 NU/ml, respectively, are considered positive.
Immunogenicity analyses were based on intent-to-treat. Re-
sponse rates were calculated based on evaluable data as listed
under immunogenicity evaluations above. Two-sided 95% confi-
dence intervals were calculated using the score test method [37].
Differences in response rates between groups were tested with
Fisher exact tests. Statistical tests were two-sided and considered
significant if P,0.05.
Results
Trial population
Between August 2005 and May 2007, the HIV Vaccine Trials
Network enrolled 264 healthy HIV-1 uninfected adults from the
US, Brazil and Thailand into two randomized, placebo controlled,
double blinded HIV vaccine trials (HVTN 060 and HVTN 063)
(220 to a vaccine regimen and 44 to placebo). As these 2 trials are
quite similar in design and utilized the same vaccine products, we
are presenting the combined data. In total, 20 participants were
randomized to 3 doses and 30 to 5 doses of gag DNA alone; 10
each to 3 doses of gag DNA and IL-12 or IL-15 DNA at an
adjuvant dose of either 100 or 500 ug; 30 to 3 doses and 30 to 5
doses of gag DNA+IL-12 DNA at the maximum dose of 1500 ug ;
10 to 3 doses and 30 to 5 doses of gag DNA+IL-15 DNA at the
1500 ug, 30 to 3 doses of gag DNA+IL-15 DNA at the 1500 ug
dose followed by 2 doses with gag DNA+IL-12 DNA (1500 ug);
and 20 to 3 doses and 24 to 5 doses of placebo (Figure 2). All
vaccinations were administered intramuscularly in the deltoid.
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age of 31 (Table 1). Participants represented a mixture of racial/
ethnic groups, with 54% being white non-Hispanic. Overall, 91%
received 3 study injections and 85% of those randomized to 5
study injection completed their regimens (Table 2). The most
common reasons for not completing vaccination were: the
participant could not be contacted (n=11; 4.2%), and the
participant was unable to schedule the vaccination visit within
the allowable visit window (n=10; 3.8%). Site investigators
discontinued vaccinations for 4 vaccine recipients due to adverse
events deemed probably not related to vaccination (manic episode,
suicide intention, decreased hemoglobin related to heavy menses,
and new onset mild type II diabetes). Two participants refused to
continue with vaccinations due to clinical events (one placebo
participant with moderate abdominal pain deemed probably not
related to vaccination and one vaccinee with mild elbow pain
deemed possibly related).
Safety
The vaccines were well tolerated. Fifteen participants on
vaccine arms and 5 receiving placebo had erythema and/or
induration of 6 cm
2 or less at the injection site. Overall, 45% of
participants had mild and 3% moderate pain and/or tenderness at
the injection site in the three days following vaccination. There
were no statistically significant differences in severity between
placebo and vaccine groups and no increase in severity with
additional doses (Figure 3A). Half of participants had no systemic
vaccine reactions, 34% had a maximum severity of mild, and 15%
had a maximum severity of moderate (Figure 3B). One gag
DNA+IL-15 DNA participant had a severe headache on day 3
following the 2
nd vaccination, which was thought to be related to
sinusitis, not vaccination. This participant received the 3
rd
vaccination with no reactions reported. One participant random-
ized to placebo inadvertently received gag DNA+IL-12 DNA at the
first two study injections and placebos at the later 3 injections due
to pharmacy errors. This participant had mild tenderness at the
injection site following the 3
rd injection (1st placebo injection) and
mild elevated SGOT deemed probably not related to study
product 2 weeks after the 3
rd injection. This participant reported
no other vaccine reactions and other adverse events were mild and
not related to product (occupational thumb pain and a cold).
Adverse Events
Thirty-nine (88.6%) of placebo subjects and 182 (82.7%) of
vaccine subjects reported at least one AE. There were no Grade 3
or 4 AEs or SAEs related to study products. The vaccine and
cytokine adjuvants did not have any apparent effects on
hematologic parameters (complete blood count, CBC), CD4+
lymphocyte counts, or serum chemistries compared to placebo.
AEs that were reported as ‘‘definitely related’’ or ‘‘probably
related’’ to vaccination were mild in severity: 1 event each of
injection site pruritis, injection site swelling, injection site pain,
injection site papule, pyrexia, and injection site hematoma. AEs
Table 1. Participant characteristics.
N( % )
Total enrolled 264
Country US 240 (90.9%)
Brazil 12 (4.5%)
Thailand 12 (4.5%)
Sex Male 142 (53.8%)
Female 122 (46.2)
Race Race
White - non-Hispanic 142 (53.8%)
African American - non-Hispanic 63 (23.9%)
Hispanic 32 (12.1%)
Other 27 (10.2%)
Age Median 31 years
minimum, maximum 18, 50 years
doi:10.1371/journal.pone.0029231.t001
Figure 3. Severity of vaccine reactions. Panel A shows the maximum severity of pain or tenderness at the injection site and Panel B the
maximum severity of systemic reactogenicity symptoms. Systemic symptoms include malaise and/or fatigue, myalgia, headache, nausea, vomiting,
chills and arthralgia. Data for vaccinations 1–3 and for vaccinations 4–5 are combined. Data for adjuvants at a dose of 100 or 500 ug are also
combined (labeled as low). Abbreviation PL=placebo.
doi:10.1371/journal.pone.0029231.g003
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were mild except as noted: CPK increased (3 events, mild to
moderate), hemoglobin decreased (3), AST increased (2), CD4
decreased (2) , neutropenia (moderate), myalgia (2), URI (2),
dizziness (2), and 1 event each for chills (moderate), fatigue
(moderate), HA (moderate), lymphocytes decreased (moderate),
injection site papule, ALT increased, arthralgia, atrial fibrillation,
back pain, hyperreflexia, nasal congestion, pharyngitis, protein-
uria, rhinorrhea, sneezing, anorexia, apthous stomatitis, chest
discomfort, abnormal UA, nausea, presyncope, metrorrhagia, and
musculoskeletal pain.
Among those who received gag DNA+IL-12, two participants
out of 68 tested for IL-12 antibody following the 1
st vaccination
had positive results. One had a low level result of 32.3 NU/ml (a
positive response was .30 NU/ml) that was not present at
baseline, or following the 2
nd or 3
rd vaccination. The other had a
result of 45.1 NU/ml but had also tested positive at baseline with a
value of 71.4 NU/ml. None tested positive following the 2
nd
vaccination (n=61 tested) or following the 3
rd vaccination (n=69
tested) and none who received 3 doses of gag DNA+IL-15 followed
by gag DNA+IL-12 (n=26 tested) tested positive after the 5
th
vaccination. With regard to IL-15 antibody, two participants
(n=26 tested) who received gag DNA+IL-15 followed by gag
DNA+IL-12 tested positive after the 5th vaccination (values of
11.5 and 17.7 NU/ml, a positive response was .11 NU/ml). On
the gag DNA+IL-15 arms, none among 29 tested who received 3
doses tested positive after the 3
rd vaccination and none among 28
who received 5 doses tested positive after the 5
th vaccination. The
presence of IL-12 antibody or IL-15 antibody was not associated
with any adverse events.
Immunogenicity
T-cell responses as measured by the Interferon-gamma (IFN-c)
ELISpot assay were minimal and of apparent short duration as
none of those assayed post 5
th vaccination had a response (Table 3).
No statistically significant differences were observed in pairwise
comparisons of response rates for gag DNA alone to the groups
receiving either IL-12 or IL-15 plasmid adjuvants following either
the 3
rd or 4
th vaccinations. One participant who received gag DNA
alone responded at both time points (background adjusted SFCs of
165 and 252/10
6 PBMC, respectively). For those receiving 5 gag
DNA+IL-15 DNA vaccinations or those receiving 3 gag DNA+IL-
15 DNA followed by 2 gag DNA+IL-12 DNA vaccinations, assays
were not performed following the 3
rd vaccination so comparisons
to the post 5
th vaccination time point are not possible. Following
three vaccinations, response rates were: 4.9% (2/41 subjects; 95%
CI 1.3%, 16.1%) for gag DNA alone and 21.1% (4/19 subjects;
95% CI 8.5%, 43.3%) for gag DNA+IL-12 DNA at either a 100 or
500 ug dose (There were 0/10 responders in the gag DNA+IL-12
DNA (100 ug) group, and 4/9 responders in the gag DNA+IL-12
(500 ug) group). No responses were observed for the gag
DNA+1500 ug IL-12 group or for any of the gag DNA+IL-15
dose groups. Following four vaccinations, the gag DNA alone
response rate was 8.7% (2/23 subjects; 95% CI 2.4%, 26.8%); for
gag DNA+1500 ug IL-15, 11.5% (3/26 subjects; 4.0%, 29.0%) and
in subjects receiving 3 gag DNA+IL-15 vaccinations followed by
vaccination with gag DNA+IL-12, 3.6% (1/28 subjects; 0.6%,
17.7%). One placebo participant responded at baseline and post
3
rd vaccination (background adjusted SFCs/10
6 PBMC 221 and
100, respectively). No responses were observed at baseline among
the 132 vaccine recipients with assay results.
We also measured humoral immune responses to gag. One
participant in the gag DNA+IL-15 followed by gag DNA+IL-12
arm had a low level ELISA response to p55 at baseline and post
4
th vaccination (background adjusted ODs 0.21 and 0.22). No
participant developed a vaccine-induced anti-gag response.
Discussion
These trials demonstrate the safety of an HIV-1 DNA vaccine
administered in combination with plasmid cytokine adjuvants.
Cytokines administered in protein form can cause severe side
effects. IL-15 shares the common gamma chain with IL-2, and
although IL-15 has never been given directly, IL-2 can cause side
effects such as fever, malaise and hypotension [38]. The use of IL-
12 protein administered intravenously at doses of 500–1000 ng/
kg has been associated with stomatitis, elevation of liver enzymes,
leukopenia, and death [39–41]. However, In pre-clinical toxicity
studies, the use of plasmid cytokine adjuvants did not result in
detectable elevations in cytokine levels systemically, and we saw
no severe reactions related to vaccination in these trials,
suggesting that any cytokine production was limited to the site
of injection.
Table 2. Number of vaccinations received.
Vaccination Number
1st 2nd 3rd 4th 5th
Gag DNA 50/50 (100.0%) 46/50 (92.0%) 44/50 (88.0%) 25/30 (83.3%) 24/30 (80.0%)
Gag DNA+IL-12(100/500 mcg) 20/20 (100.0%) 20/20 (100.0%) 19/20 (95.0%) NA NA
Gag DNA+IL-12(1500 mcg) 60/60 (100.0%) 57/60 (95.0%) 53/60 (88.3%) 24/30 (80.0%) 24/30 (80.0%)
Gag DNA+IL-15(100/500 mcg) 20/20 (100.0%) 20/20 (100.0%) 20/20 (100.0%) NA NA
Gag DNA+IL-15(1500 mcg) 70/70 (100.0%) 69/70 (98.6%) 66/70 (94.3%) 28/30 (93.3%) 26/30 (86.7%)
+Gag DNA+IL-12(1500 mcg) boost
at 4
th &5
th vaccinations
26/30 (86.7%) 25/30 (83.3%)
Placebo 44/44 (100.0%) 41/44 (93.2%) 39/44 (88.6%) 23/24 (95.8%) 23/24 (95.8%)
Total 264/264 (100.0%) 253/264 (95.8%) 241/264 (91.3%) 126/144 (87.5%) 122/144 (84.7%)
Abbreviations: NA – not applicable.
For vaccinations 1, 2 and 3, the denominator is the number of persons randomized to receive either 3 or 5 study injections.
For vaccinations 4 and 5, the denominator is the number randomized to 5 study injections.
The numerator is the number of people who actually received the specified vaccination.
doi:10.1371/journal.pone.0029231.t002
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with previous findings in macaques. Shadeck et. al. immunized
groups of 5 macaques with either low dose (1.5 mg) or high dose
(5 mg) SIV gag p39, which was codon optimized in a manner
similar to the HIV gag p37 construct used in this human trial, with
or without 1.5 mg or 5.0 mg of IL-12 plasmid DNA. The
administration of plasmid IL-12 at low dose in combination with
low dose HIV DNA led to cellular immune responses in all
animals, with a mean value 5-fold higher than macaques
immunized with high dose SIV gag DNA alone. The increased
magnitude of immune responses was associated with increased
breadth of responses as measured by the number of individual
overlapping peptides recognized by vaccinated animals. The
ability of low dose pIL-12 in combination with SIV DNA to elicit
responses superior to DNA alone results in a significant dose-
sparing effect that allows lower doses of DNA to be used, or allows
the incorporation of DNAs expressing additional HIV/SIV gene
products [42]. In macaques, IL-15 administered as plasmid
cytokine adjuvant with SIV gag DNA marginally increased the
magnitude of antigen-specific interferon-gamma producing T cells
compared with SIV gag DNA alone [43,44]. It was not as potent as
SIV DNA administered with pIL-12, and there was no significant
difference in the magnitude of responses when pIL-15 was co-
administered with pIL-12 [43]. However, cells from macaques
primed with SIV gag DNA+pIL-15 show enhanced ability to
proliferate in vitro compared to SIV gag DNA alone, suggesting
that pIL-15 delivered as an adjuvant may qualitatively affect the
vaccine-induced immune response [44].
Despite promising results in macaque studies of a similar SIV
gag DNA at similar doses, we found limited immunogenicity after
administration of the combination of HIV gag DNA with either
IL-12 or IL-15 or both. For many vaccines, not limited to DNA,
there is a marked difference in the magnitude of immune
responses between macaques and humans [14], so immune
responses elicited by vaccination may be quite different for
unknown species-specific reasons. Other trials have noted a lack
of gag responses after DNA vaccination with different gag DNA
constructs from the one we tested in this trial, and this may
reflect something inherently different about the human response
to gag HIV DNA [8,16]. We also may have been limited by the
use of a truncated form of gag, which did not include several
dominant HIV epitopes present in areas outside of p37 (http://
www.hiv.lanl.gov/content/immunology/tables/ctl_summary.
html) [45] and not incorporating other insert antigens which
m a yb em o r ei m m u n o g e n i c ,s u c ha se n v e l o p e[ 8 ] .I ti su n i k e l y
that the lack of immunogenicity was due to a lack of expression
of the gag HIV DNA. In vitro expression analyses of the HIV gag
p37 DNA was performed in both African green monkey kidney
(COS) and human rhabdomyosarcoma (RD) cells. There was
significant enhancement in Gag expression (up to 200-fold) with
the RNA-optimized gag p37 over that observed with the original
full-length HIV-1 gag DNA, and this was the reason for going
forward with this particular study product. In macaque trials
without plasmid cytokine adjuvant, higher doses of DNA
improved the magnitude of immune responses, and higher
concentrations of HIV DNA may improve immunogenicity in
future trials [43].
Despite the theoretical advantages of DNA vaccination, and
the apparent immunogenicity of these vaccines in animals,
significant improvements will be necessary if these vaccines are to
enter larger clinical trials as a standalone regimen. There have
been some responses to HIV DNA, but mainly limited to
Envelope responses [8,16]. Recent studies have shown that while
DNA alone is a very poor immunogen in humans, as part of a
prime-boost strategy with Adenovirus or MVA, it can signifi-
cantly increase the magnitude and quality of the immune
response [16,17]. The cytokine plasmid approach has been quite
successful in macaques, and here too, more concentrated versions
of these plasmid cytokine adjuvants or more careful timing of
cytokine administration may be required to induce robust
responses in humans. Other adjuvants currently in testing include
TLR agonists, or other cytokine plasmids such as IL-28 as
recently published by Morrow et. al. [19].
Another approach toward DNA vaccination may rely on the
delivery method of DNA. Recent studies have shown electropo-
ration to be highly efficient at inducing immune responses in
animal models, with up to 40-fold higher frequencies of cytokine-
producing T cells [46,47]. In a recent macaque study comparing
4 doses of SIV DNA vaccination delivered via in vivo
electroporation to 3 doses of Ad5-SIV vaccination, peak immune
responses to SIV gag were 2.5 fold higher, and peak responses to
SIV pol 5.5 fold higher in the DNA-EP vaccinated group [48]. In
addition to the higher magnitudes of responses as measured by
IFN-c ELISpot, SIV-DNA delivered via EP induced immune
Table 3. IFN-c ELISpot response.
Post 3
rd vaccination Post 4
th vaccination Post 5
th vaccination
Response rate (95% CI)
Background
adjusted SFC/10
6
PBMC for
responders Response rate (95% CI)
Background
adjusted SFC/10
6
PBMC for
responders Response rate (95% CI)
Gag DNA 2/41=4.9% (1.3%, 16.1%) 165, 178.5 2/23=8.7% (2.4%, 26.8%) 76.5, 252 0/21=0.0% (0.0%, 15.5%)
Gag DNA+IL-12 (100 mcg) 0/10=0% (0%, 27.8%) NA NA
Gag DNA+IL-12 (500 mcg) 4/9=44.4% (18.9%, 73.3%) 55, 57.5, 61.5, 103.5 NA NA
Gag DNA+IL-12 (1500 mcg) 0/49=0.0% (0.0%, 7.3%) 0/24=0.0% (0.0%, 13.8%) 0/23=0.0% (0.0%, 14.3%)
Gag DNA+IL-15 (100/500 mcg) 0/18=0.0% (0.0%, 17.6%) NA NA
Gag DNA+IL-15 (1500 mcg) 0/6=0.0% (0.0%, 39.0%) 3/26=11.5% (4.0%, 29.0%) 61, 147.5, 195 ND
+Gag DNA+IL-12 (1500 mcg)
at 4
th &5
th vaccinations
1/28=3.6% (0.6%, 17.7%) 71.5 ND
Placebo 1/23=4.3% (0.8%, 21.0%) 100 0/24=0.0% (0.0%, 13.8%) 0/11=0.0% (0.0%, 25.9%)
Abbreviations: CI-confidence interval; SFC-spot forming cells; NA-not applicable for those randomized to 3 vaccinations; ND-assay not performed.
doi:10.1371/journal.pone.0029231.t003
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Ad5-SIV as measured by antigen-specific secretion of TNF-a,
Mip-1a, and IL-2, along with enhanced antigen-specific
proliferation [48]. A recent small trial in humans showed
HIV DNA delivered via IM electroporation to be safe and
more immunogenic than DNA delivered via standard IM
vaccination [29].
These data suggest that IL-12 and IL-15 are safe to give, but
offered little ability to augment cellular immune responses in this
format. The results of human vaccine trials currently in progress
with DNA delivered via electroporation, with and without plasmid
cytokine adjuvant, will help us determine whether DNA
vaccination can induce cellular immune responses either alone
or as part of a prime-boost regimen.
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